Site-Specific Conjugation to Cys-Engineered THIOMAB™ Antibodies

Pragya Adhikari; Neelie Zacharias; Rachana Ohri; Jack Sadowsky

doi:10.1007/978-1-4939-9929-3_4

Site-Specific Conjugation to Cys-Engineered THIOMAB™ Antibodies

Methods Mol Biol. 2020:2078:51-69. doi: 10.1007/978-1-4939-9929-3_4.

Authors

Pragya Adhikari¹, Neelie Zacharias¹, Rachana Ohri¹, Jack Sadowsky²

Affiliations

¹ Department of Protein Chemistry, Genentech, Inc., South San Francisco, CA, USA.
² Department of Protein Chemistry, Genentech, Inc., South San Francisco, CA, USA. sadowsky.jack@gene.com.

PMID: 31643049
DOI: 10.1007/978-1-4939-9929-3_4

Abstract

Antibodies bearing engineered cysteine residues (termed THIOMAB™ antibodies) enable the site-selective attachment of a drug, label or other payload for specific delivery to certain tissues (e.g., tumors). This Chapter describes detailed methods we have developed and optimized for the conjugation, purification and analysis of THIOMAB™ antibody drug conjugates (TDCs).

Keywords: ADC; Disulfide; Engineered cysteine; Maleimide; Site-specific conjugation; THIOMAB.

MeSH terms

Antibodies, Monoclonal / chemistry*
Bioengineering
Chromatography
Cysteine / chemistry*
Drug Development*
Genetic Engineering
Humans
Immunoconjugates / chemistry*
Immunoconjugates / isolation & purification
Immunoconjugates / pharmacology

Substances

Antibodies, Monoclonal
Immunoconjugates
Cysteine